{"blog": [], "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Valeant Pharmaceuticals International Inc", "name": "organizations", "rank": "2", "is_major": "Y"}, {"value": "Securities and Exchange Commission", "name": "organizations", "rank": "3", "is_major": "Y"}, {"value": "Pearson, John Michael (1959- )", "name": "persons", "rank": "4", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/03/01/business/valeant-pharmaceuticals-is-under-sec-investigation.html", "document_type": "article", "byline": {"person": [{"lastname": "THOMAS", "firstname": "Katie", "role": "reported", "organization": "", "rank": 1}], "original": "By KATIE THOMAS"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbWide.jpg", "legacy": {"wide": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-articleLarge.jpg", "legacy": {"xlarge": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 400}, {"url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "641", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "The beleaguered drug maker, already under scrutiny for its steep price increases, earlier canceled its fourth-quarter earnings report.", "pub_date": "2016-03-01T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "<span data-tag=\"tight__4\">After Tumultuous Day for Valeant, Latest Blow Is an S.E.C. Investigation</span>", "main": "Valeant Pharmaceuticals Is Under S.E.C. Investigation"}, "print_page": "3", "snippet": "The beleaguered drug maker, already under scrutiny for its steep price increases, earlier canceled its fourth-quarter earnings report.", "_id": "56d4c6f438f0d811294b816c", "slideshow_credits": null, "abstract": "Valeant Pharmaceuticals says it is being investigated by Securities and Exchange Commission; has come under scrutiny for its high drug prices and dealings with mail-order pharmacy."}